All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Professor Miles Prince is the Director of the Centre for Blood Cell Therapies at the Peter MacCallum Cancer Centre, Melbourne, AU, Director of Molecular Oncology and Cancer Immunology at Epworth Hospital, Melbourne, AU, as well as Professor at both University of Melbourne and Monash University, Melbourne, AU. Prof. Prince obtained a BSc in Medicine (Hons), a BSc in Surgery (Hons), and a Doctor of Medicine from Monash University. He trained in Melbourne, Sydney, AU and Toronto, CN.
Prof. Prince treats all types of blood disorders, including anemia, blood clots, and all blood-related cancers. He runs an active research group in stem cell research for the development of and better understanding of the role of the immune system in blood cancer development. In 1995, he set up the Centre for Blood Cell Therapies at Peter MacCallum Cancer Centre, which includes GMP laboratories for cell-based therapies including CAR T-cell protocols. His clinical research focuses on myeloma, T-cell lymphoma, and immune-based therapies.
Positions of responsibility/awards:
Steering committee member of Multiple Myeloma Hub